$313.6B API Market: 7.1% CAGR by 2027

$313.6B API Market 7.1% CAGR by 2027

This 223-page report, “Global Active Pharmaceutical Ingredients (API) Market 2021-2027 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Region: Trend Forecast and Growth Opportunity,” is highlighted by 150 tables and 101 figures and is based on a thorough analysis of the entire global Active Pharmaceutical Ingredients (API) Market and all of its sub-segments through extremely detailed classifications. Premium primary and secondary information sources are used to create in-depth research and assessment, with input coming from business specialists working across the value chain.

Due to the rising demand for medications and pharmaceutical agents in the wake of the COVID-19 pandemic, the global market for active pharmaceutical ingredients (API) will reach $313.6 billion by 2027, expanding at a revised 7.1% CAGR from 2020 to 2027.

The Active Pharmaceutical Ingredients (API) Market report uses 2020 as its base year for forecasts from 2021 to 2027 and is based on investigations from 2017 to 2020. (Please note that the report will be updated before to delivery to ensure that the forecast includes at least 5 years past the base year and the most recent historical year serves as the base year.)

Request Research Sample with Latest Industry Insights (223+ Pages Report): https://altusmarketresearch.com/reports/sample/3429

The following aspects are identified and examined in-depth qualitative analyses:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

By taking COVID-19 into consideration, the trend and outlook for the global market are predicted with an upbeat, fair-minded, and conservative viewpoint. The global API market is quantified from all angles, including synthesis, manufacturing process, therapeutic use, drug type, and region, using the balanced (most likely) projection.

The global Active Pharmaceutical Ingredients (API) Market is divided into the following sub-markets based on Synthesis, with annual revenue for each part for the years 2017 to 2027.

Synthetic API
• Branded Synthetic API
• Generic Synthetic API
Biotech API by Drug Type:
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Other Biotech APIs
Biotech API by Customer Base:
• Innovative Biologic API
• Generic Biosimilar API
Biotech API by Expression Technology:
• Mammalian Expression
• Microbial Expression
• Yeast Expression
• Insect Expression
• Other Expression Technologies
HPAPI
• Branded HPAPI
• Generic HPAPI

Based on Manufacturing Process, the global Active Pharmaceutical Ingredients (API) Market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section.

Captive Manufacturing
• Branded Captive API
• Generic Captive API
Merchant Manufacturing by Drug Type:
• Branded Merchant API
• Generic Merchant API
Merchant Manufacturing by Drug Synthesis:
• Merchant Synthetic API
• Merchant Biotech API

Based on Therapeutic Application, the global Active Pharmaceutical Ingredients (API) Market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section.

• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Orthopedics
• Other Applications

Based on Drug Type, the global Active Pharmaceutical Ingredients (API) Market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section.

• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs

Along with the listed national/local markets, the following geographic areas are thoroughly investigated:

• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
In Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
• America, North (U.S., Canada, and Mexico)
Latin America (Brazil, Chile, Argentina, Rest of South America)
• RoW (Saudi Arabia, UAE, South Africa) (Saudi Arabia, UAE, South Africa)

There are thorough analyses and data for annual revenue for each of the aforementioned regions and nations for the years 2017 through 2027. All regional markets are broken down by country, and major national markets are divided according to Synthesis, Manufacturing Process, and Therapeutic Application over the course of the predicted years.

The study also analyses the present competition landscape, the anticipated trend, and it provides profiles of key vendors, including both established market leaders and significant up-and-coming companies.

Through AMR’s Risk Assessment System, possible risks related to investing in the worldwide API industry are specifically assessed statistically and qualitatively. Critical Success Factors (CSFs) are developed based on the risk analysis and evaluation as a guide to assist investors and stockholders in identifying emerging possibilities, managing and minimising risks, developing suitable business models, and making informed strategies and decisions.

Key Players (this list may not be exhaustive; additional businesses can be included upon request):

AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
BASF
Bayer AG
Boehringer Ingelheim
Dr. Reddy’s Laboratories
F. Hoffmann-La Roche
GlaxoSmithKline plc
Lonza Group
Lupin Limited
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.